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Accidental cisplatin overdose has been occurring with an increasing frequency due to expanding usage of the agent. However, the
optimal strategy to treat such patients remains to be established. Here, we report a case of large cisplatin overdose, successfully
managed by plasma exchange, intravenous hydration, granulocyte colony-stimulating factor (G-CSF) administration, and other
supportive care. A 67-year-old man with esophageal carcinoma received a large cisplatin overdose of 240mg/m
2, when he received
adjuvant therapy following subtotal esophagectomy. On day 4, he experienced frank cisplatin toxicities and emergency plasma
exchange was initiated. With 7 cycles of plasma exchange, the cisplatin concentration decreased from 2,350 to 110ng/mL. Severe
bone marrow suppression with high fever ensued on day 10, which was successfully treated with G-CSF and antibiotics. Despite
moderate hearing sense reduction, he recovered without signiﬁcant complications. Immediate plasma exchange with hydration
and other care was eﬃcacious in quickly lowering cisplatin concentrations.
1.Introduction
Cis-diamminedichloroplatinum (II) (cisplatin) represents
one of the most widely used and eﬀective antineoplastic
agents. The heavy metal platinum causes interstrand cross-
linking of DNA, thereby preventing tumor cell proliferation
[1]. Preclinical data suggest that cisplatin has a steep dose-
response relationship for ovarian cancer and other tumors
[2]. However, despite vigorous intravenous hydration and
mannitol treatment, acute nephrotoxicity and chronic renal
damageoftenoccurafteradministrationoftherapeuticdoses
ofcisplatin,100to120mg/m2 peronecycleofchemotherapy
[3]. In particular, higher doses of cisplatin due to acciden-
tal overdose have been reported to cause nephrotoxicity,
neurotoxicity, ototoxicity, gastrointestinal disturbances, and
severe myelosuppression [4]. Although there are reports
describing that patients receiving massive cisplatin overdose
were successfully rescued [4–8], the optimal strategy to treat
overdosed patients remains to be established.
Here, we report a 67-year-old man who suﬀered an
accidental cisplatin overdose of 240mg/m2. Although the
patient was left with moderately reduced sense of hearing, he
ultimately recovered without signiﬁcant complications with
plasma exchange combined with intravenous hydration, G-
CSF administration, and other supportive care.
2.CaseReport
A 67-year-old man was diagnosed with stage II esophageal
carcinoma (T1N2M0). Endoscopic examination showed a
white plaque lesion spreading from 35 to 37cm from
incisors after spraying of Lugol’s iodine solution. No spread
beyond the adventitia was apparent with both computed
tomography (CT) and positron emission tomography exam-
inations. However, metastatic lymph node involvements
in regions I and III were noted. Histopathology revealed
well-diﬀerentiated squamous cell carcinoma. He underwent
subtotal esophagectomy and was diagnosed to be at post-
operative stage IIIa (pT3N3M0). He subsequently received
postoperative adjuvant chemotherapy. The patient was put
in a treatment protocol consisting of cisplatin 80mg/m2 on
day 1 and 5-ﬂuorouracil (5-FU) 800mg/m2 from days 1 to 5.2 Case Reports in Medicine
However, he was inadvertently administered with cisplatin
80mg/m2 plus 5-FU 800mg/m2 for consecutive 3 days,
which fell upon Saturday, Sunday, and a national holiday in
Japan. On day 4, which was Tuesday, the patient complained
that he had hearing diﬃculty, and the cisplatin over-
dose was noted, and further chemotherapy was disrupted
(Figure 1(a)). The patient was immediately transferred into
a laminar ﬂow clean room. Ototoxicity, nonoliguric renal
failure, hepatic dysfunction, and acute pancreatitis were
identiﬁed. Laboratory test revealed his BUN of 40.2mg/dL,
creatinine 1.99mg/dL (175.9μM/L), AST 251U/L, ALT
229U/L, total bilirubin 0.6mg/dL, amylase 178U/L, and
LDH 445U/L. Hemodialysis and detoxiﬁcation with sodium
thiosulfate (STS) were performed on the same day and
emergency plasma exchange was implemented on day 5
(Figure 1(a)).
His plasma and urine total platinum concentrations were
examined with ﬂameless Zeeman atomic absorption spec-
trophotometry using Simultaneous Multielement Atomic
Absorption Spectrometer 6000 (PerkinElmer. Inc., MA,
USA). His plasma cisplatin concentration was 2,350ng/mL
after a cycle of hemodialysis and treatment with STS.
On days 5 through 19, the patient underwent plasma
exchange seven times and his plasma cisplatin concentration
decreased to 110ng/mL (Figure 1(a)). It was noted that his
plasma cisplatin concentration was abruptly decreased after
2 cycles of plasma exchange; however, despite daily plasma
exchange conducted, an increase of cisplatin concentration
was observed twice, on days 8 and 10 (Figure 1(a)).
His cisplatin excretion in urine was 4.8mg/day on day 6.
Of note, on day 15, when his plasma cisplatin concentration
droppedbelow180ng/mL,cisplatinexcretioninhisurineyet
persisted from 1.5mg/day to 1.8mg/day. On day 12, severe
leukocytopenia occurred and the administration of granu-
locyte colony stimulating factor (G-CSF) was implemented.
Leukopenia was noted on days 10–13 with WBC counts
of ∼2,000/mL and slowly worsened afterward. On day 14,
he developed high fever with infectious focuses unknown
and his granulocyte counts were of ∼10/μL, which persisted
over 3 days despite the G-CSF administration (Figure 1(a)).
Administration of broad-spectrum antibiotics (vancomycin
and meropenem) was begun and his fever resolved by day
21. The patient was kept on fasting until day 19 because of
mucositis that was thought to have resulted from cisplatin
overdose and bacterial infection.
After undergoing seven cycles of plasma exchange, his
creatinine levels fell to 1.8mg/dL (159.1μM/L) and his cre-
atinine clearance got stabilized at 35mL/minute. His serum
levels of AST, ALT, and amylase were 240U/L, 280U/L, and
527U/L, respectively, as examined on day 5; however, they
became normal by day 10. He slowly recovered from his
initial hearing loss, and after a month he subjectively did
not perceive distinct ototoxicity. However, when his auditory
acuitywasevaluated,asigniﬁcantacuityreductionwasnoted
at high frequency ranges. His left/right auditory acuity levels
were 20/35, 40/30, 30/30, 60/55, and 80/75dB at 500, 1,000,
2,000, 4,000, and 8,000Hz (normal auditory acuity levels are
between 0–20dB at each range: the greater the value, the
more compromised the hearing acuity).
His general conditions slowly but steadily improved
without any further life-threatening complications arising
from the cisplatin overdose and he was transferred into
a general ward on day 28. Then, he was discharged later
because of the eating disorders due to an esophageal
stricture.
3. Discussion
Toxicities of cisplatin include emesis, nephrotoxicity, neu-
rotoxicity, hearing loss, visual impairment, cholestasis, gas-
trointestinal disturbances, and bone marrow suppression
[2]. The most serious complication is nephrotoxicity, which
may result in irreversible renal failure [9, 10]. Patients inad-
vertently receiving less than 300mg/m2 of cisplatin report-
edly often recover, whereas overdoses exceeding 400mg/m2
frequently result in death [2–7, 9, 11]( Table 1). As the
toxicity of cisplatin is dose-dependent, early elimination of
the drug from plasma should be critical in the management
[12].
Reportedly, most of the platinum in the blood plasma
is bound to proteins within a few hours after intravenous
administration [4, 13]. The binding of cisplatin to proteins
reduces urinary excretion of platinum and causes deposition
of platinum in tissues. Binding of cisplatin to proteins and
enzymesisgenerallybelievedtobethecauseofitssideeﬀects,
especiallyototoxicityandnephrotoxicity.Theprotein-bound
form cisplatin cannot be removed by hemodialysis [2, 4,
8, 14, 15]. Thus, hemodialysis is not eﬀective in removing
the protein-bound platinum; however, plasma exchange has
been thought to be eﬃcacious in treatment of cisplatin
overdose. Indeed, in the present case, the plasma cisplatin
concentration was as high as 2,350ng/mL after one cycle
of hemodialysis on day 4, while the plasma cisplatin con-
centration had decreased to 360ng/mL after two cycles of
plasma exchange (Figure 1(a)). Paradoxically, an increase
of plasma cisplatin concentration was observed twice, on
days 8 and 10 despite of daily plasma exchange conducted.
These results suggest that cisplatin deposited in tissues and
intracellular cisplatin [2, 6] were being continuously released
to plasma. It is noteworthy that afterwards his plasma
cisplatin concentration slowly but constantly decreased.
It is argued as to how many cycles of plasma exchange
are required to suﬃciently decrease cisplatin to nontoxic
levels. Therefore, we believe that early and continuous
plasma exchange is useful in the management of cisplatin
overdose.
A number of thiols, including N-acetylcysteine, STS, and
mesna, all of which bind to circurating reactive cisplatin
derivatives, have been studied as chemoprotectants [7, 9].
These protectants are given before or during the administra-
tion of cisplatin.
In the present case, STS was administered on day 4;
however, the eﬃcacy of the administration in the present
case is unclear [11]. Erdlenbruch et al. demonstrated that
STS administrated 70 hours after an overdose had an eﬀect
in improving renal functions [7]. Nevertheless, there is no or
littleevidencethatchemoprotectantscanreversehearingloss
[16]. Moreover, it is of note that the use of chemoprotectantCase Reports in Medicine 3
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Figure 1: Plasma cisplatin concentrations, leukocyte counts, Ccr values and platinum clearance values. (a) An open diamond and arrow heads
denote for dialysis and plasma exchange, respectively. (b) Note that cisplatin clearance approximately correlated with Ccr. WBC: white blood
cell, G-CSF: granurocyte-colony-stimulating factor, Ccr: creatinine clearance.
Table 1: Selected literature of cisplatin overdose; PE: plasma exchange; HD: hemodialysis. STS: sodium thiosulfate.
Authors Dose of cisplatin Treatment Outcome
Schiller et al. 480mg/m2 PE, HD Alive, irreversible hearing loss
Chu et al. 280mg/m2 PE, HD Alive, irreversible hearing loss
Lagrange et al. 205mg/m2 HD Alive
Jung et al. 300mg/m2 PE Alive
Sheikh-Hamad et al. 400mg/m2 N-acetylcysteine Dead
Choi et al. 400mg/m2 PE, HD Alive
Erdlenbruch et al. 360mg/m2 STS Alive
Charlier et al. 750mg/body PE, HD, N-acetylcysteine Dead
Hofmann et al. 225mg/m2 PE Alive
Our patient 240mg/m2 PE, HD, STS Alive
alonemayimposeoverloadtothekidneyofpatientssincethe
elimination of cisplatin mostly occurs through the kidney,
whose functions may have already been compromised by the
toxicity of the agent.
As shown in Figure 1(b), the platinum clearance of
the patient, which was calculated as platinum excreted per
minutesdividedbyplasmaplatinumconcentration,approxi-
mately correlated with creatinine clearance (Ccr). Signiﬁcant
amounts of platinum were excreted in the urine. While the
plasma cisplatin concentration was as low as <180ng/mL,
the amounts of cisplatin excreted into urine were persistently
>1.5mg/day after Ccr was improved. Thus, in removing
cisplatin as quickly as possible, suﬃcient hydration should
be continued and Ccr levels should be cautiously monitored
even after plasma cisplatin concentrations became appar-
ently within or close to normal ranges.
In the present case, we withheld the use of G-CSF until
day 12, when the patient developed leucopenia. It is argued
as to whether the administration of G-CSF should be imple-
mented as soon as cisplatin overdose is revealed [6]. It is
possible that stimulating hematopoietic cells to proliferate in
the presence of toxic agents results in more substantial dam-
age of such cells. It is known that certain anticancer agents
such as cytarabine exert greater toxicity to granulocytes
and granulocytic tumor cells when used with G-CSF [17].
Antiviral activity against human immunodeﬁciency virus of
a nucleoside analogue, azidothymidine, is also potentiated
in macrophages/monocytes when such cells are stimulated
by granulocyte-macrophage-colony stimulating factor (GM-
CSF) [18]. Another reason we withheld the use of G-CSF in
the present case was that the patient had suﬃcient numbers
of granulocytes and no signs of infections for a week after4 Case Reports in Medicine
cisplatin overdosing, and we thought the administration of
G-CSF was unnecessary. Indeed, G-CSF was started on day
12, when the patient had developed substantial leucopenia
whenhisplasmaplatinumconcentrationhaddecreasedfrom
its peak to 210ng/mL.
Upon cisplatin overdose, the attempt of immediate,
continuous, and suﬃcient removal of the drug is an
important factor for the management of the overdose. In
the present case, adverse events resulting from the overdose
were successfully treated with vigorous plasma exchange
combined with G-CSF administration and other supportive
care. In order to prevent the recurrence of such an accident,
it cannot be overemphasized that rigorous check systems and
careful monitoring are essential when patients are treated
with cytotoxic therapeutics.
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